This book presents the views of leading European experts on the diagnosis and management of testicular cancer, with coverage of current hot topics in the field. It opens by providing an overview of the recommendations in the most recent consensus paper from the European Germ Cell Cancer Consensus Group, which is based on interdisciplinary cooperation among urologists, medical oncologists, radio-oncologists, pathologists, and basic scientists. The remainder of the book focuses on areas of controversy in the diagnosis, treatment, and follow-up of testicular cancer. In each case the evidence base is discussed and results from the most recent studies are reviewed, drawing attention to new findings that might alter treatment recommendations. The treatment-related chapters cover a broad range of issues, including the best approach in patients with poor-prognosis and recurrent disease and those with long-term toxicities. Relevant aspects of survivorship care are also addressed. The book will help clinicians and practitioners to achieve the goals of minimizing therapy and its side-effects without reducing efficacy in low stage disease, improving the cure rate in advanced disease, and enhancing follow-up and long-term survivorship.
Auflage
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Zielgruppe
Für Beruf und Forschung
Professional/practitioner
Illustrationen
9
9 farbige Abbildungen
VIII, 135 p. 9 illus. in color.
Maße
Höhe: 241 mm
Breite: 160 mm
Dicke: 14 mm
Gewicht
ISBN-13
978-3-319-17466-2 (9783319174662)
DOI
10.1007/978-3-319-17467-9
Schweitzer Klassifikation
Part I: Overview of the latest recommendations of the European Germ Cell Cancer Group.- Part II: Special topics about controversial aspects, new results from studies, which might change treatment recommendations and long-term-survivorship: Is there still an indication for radiotherapy in seminoma CS I/ IIA/B?- How should we treat nonseminoma CSI?.- Is there still an indication for diagnostic RPLND in nonseminoma CSI?.- How could the prognosis of patients with intermediate risk disease be improved?.- How should patients with poor-prognosis disease be treated actually?.- How should patients with recurrent disease be treated actually?.- How important are prognostic factors for determining treatment in patients with primary or recurrent disease?.- What should be the boundaries in retroperitoneal residual tumor resection in nonseminoma?.- How should residual disease outside the retroperitoneum be treated?.- What are the recent recommendations for follow up in testicular cancer?.- What are the long-term toxicities to be controlled and treated?.- Consequences of the disease and its treatment concerning sexuality and fertility.
